Rice Hall James & Associates LLC Purchases Shares of 189,907 LeMaitre Vascular, Inc. $LMAT

Key Points

• Rice Hall James & Associates acquired 189,907 shares of LeMaitre Vascular in the second quarter, valued at approximately $18.2 million and representing 0.83% of the company. Institutional investors collectively own 84.64% of LMAT.
• LeMaitre Vascular’s latest quarterly results fell short of expectations, with EPS of $0.74 versus an $0.81 consensus estimate and revenue of $70.38 million versus $71.47 million expected. Revenue nevertheless increased 9.6% year over year.
• The company declared a quarterly dividend of $0.25 per share, equivalent to a $1.00 annualized payout and a 1.2% yield. Analysts’ average rating is Hold, with an average price target of $110.60.

Rice Hall James & Associates LLC acquired a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 189,907 shares of the medical instruments supplier's stock, valued at approximately $18,223,000. Rice Hall James & Associates LLC owned 0.83% of LeMaitre Vascular at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Sound Income Strategies LLC boosted its holdings in shares of LeMaitre Vascular by 425.6% during the 1st quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier's stock worth $25,000 after buying an additional 183 shares during the period. Catalyst Capital Advisors LLC bought a new position in LeMaitre Vascular in the 1st quarter valued at about $32,000. Geneos Wealth Management Inc. raised its holdings in LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock valued at $47,000 after acquiring an additional 398 shares during the period. EverSource Wealth Advisors LLC acquired a new stake in LeMaitre Vascular during the second quarter worth approximately $47,000. Finally, Quarry LP lifted its position in LeMaitre Vascular by 267.2% during the third quarter. Quarry LP now owns 727 shares of the medical instruments supplier's stock worth $64,000 after acquiring an additional 529 shares during the last quarter. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular Stock Up 0.2%

Shares of LMAT opened at $82.51 on Tuesday. The company has a current ratio of 16.31, a quick ratio of 13.96 and a debt-to-equity ratio of 0.40. LeMaitre Vascular, Inc. has a 12 month low of $78.65 and a 12 month high of $118.01. The firm's 50 day moving average is $95.25 and its 200-day moving average is $99.75. The stock has a market capitalization of $1.89 billion, a PE ratio of 28.95, a P/E/G ratio of 2.38 and a beta of 0.53.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.81 by ($0.07). The company had revenue of $70.38 million during the quarter, compared to the consensus estimate of $71.47 million. LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The company's quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.60 earnings per share. Equities research analysts forecast that LeMaitre Vascular, Inc. will post 2.89 EPS for the current year.

LeMaitre Vascular Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 3rd. Stockholders of record on Thursday, August 20th will be given a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Thursday, August 20th. LeMaitre Vascular's dividend payout ratio is presently 35.09%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on LMAT. Citigroup reaffirmed a "market outperform" rating on shares of LeMaitre Vascular in a research report on Tuesday, July 21st. Barrington Research downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Wednesday, August 5th. Citizens Jmp upped their price objective on LeMaitre Vascular from $118.00 to $127.00 and gave the company a "market outperform" rating in a report on Wednesday, May 6th. Zacks Research lowered LeMaitre Vascular from a "strong-buy" rating to a "hold" rating in a report on Monday, July 6th. Finally, Wells Fargo & Company lowered their price objective on LeMaitre Vascular from $104.00 to $94.00 and set an "equal weight" rating on the stock in a research report on Wednesday, August 5th. Three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, LeMaitre Vascular has an average rating of "Hold" and an average target price of $110.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source